Phase Ib/II Study of NT219 in Combination with Pembrolizumab or Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Objective Response Rate following treatment with NT219 plus pembrolizumab (cohort 1) or cetuximab (cohort 2).
Why this Research Matters
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Who can Participate
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT06919666?term=NCT06919666&rank=1
Study ID
Protocol Number: 24-0689
More information available at ClinicalTrials.gov: NCT06919666
Meet the Team
Principal Investigator